Exanta

For decades, the standards of antithrombotic therapy have been heparin and coumarin compounds, primarily warfarin (1). Other… Expand

Atrial fibrillation is the most common sustained cardiac arrhythmia and the most frequently encountered cause of embolic stroke… Expand

Thrombosis is the leading cause of death from heart attacks and strokes. Warfarin (coumadin), the only marketed oral… Expand

It is rare for any drug introduced more than 50 years ago to remain unsurpassed today; yet the oral prevention and treatment of… Expand

INTRODUCTION The effect of the oral direct thrombin inhibitor (DTI) ximelagatran (Exanta, AstraZeneca) on the endogenous thrombin… Expand

Ximelagatran (Exanta™, AstraZeneca), an oral direct thrombin inhibitor for the prevention and treatment of thromboembolic… Expand

Thromboembolic disorders continue to be a major cause of morbidity and mortality, resulting in an increased need for… Expand

The phase III trial EXPRESS was a randomised, double-blind comparison of two anticoagulant therapies used as prophylaxis against… Expand

There are many well-known drawbacks associated with the currently used antithrombotic agents, warfarin, heparin, and low… Expand

The oral direct thrombin inhibitor (oral DTI) ximelagatran (Exanta, AstraZeneca) is rapidly absorbed and bioconverted to its… Expand